Jing Ji Guan Cha Wang·2025-12-19 01:36Group 1 - The core point of the article is the appointment of Wang Lai as the new President and Global Head of R&D at BeiGene, effective January 1, 2026, with a significant compensation package [1] - Wang Lai will receive an annual salary of $750,000 (approximately 5.28 million RMB) and is eligible for an annual target bonus equivalent to 75% of his base salary [1] - BeiGene will grant Wang Lai a one-time equity incentive of $10 million in the form of restricted stock units [1] Group 2 - Prior to his appointment, Wang Lai served as the Global Head of R&D at BeiGene since April 2021 and has held various leadership roles in R&D since joining the company in 2011 [2] - Wang Lai has an impressive academic background, having obtained a Bachelor's degree from Fudan University and a Ph.D. from the University of Texas Health Science Center [2] - He was a key leader in the development of the important drug, Zebrutinib, and was encouraged by BeiGene's co-founder, Wang Xiaodong, to return to China to help establish the company [2]